Orchestra Biomed Holdings, Inc. (OBIO) Stock Price & Analysis
Orchestra Biomed Holdings, Inc. (OBIO) rose 2.75% to USD 3.74 as of July 26, 2026 at 10:22 UTC, according to Nexqual real-time market data.
OBIO last closed at USD 3.64; the session ranged USD 3.62–3.79 on volume of 143,985 shares. Market capitalization is $223.95M, with a 52-week range of USD 2.2–5.42 (NGM). Source: Nexqual, July 26, 2026 at 10:22 UTC.
Key Statistics (as of July 26, 2026 at 10:22 UTC)
| Price | USD 3.74 |
|---|---|
| Change | ▲ 2.75% (up) |
| Previous Close | USD 3.64 |
| Open | USD 3.67 |
| Day Range | USD 3.62 – 3.79 |
| 52-Week Range | USD 2.2 – 5.42 |
| Volume | 143,985 shares |
| Market Cap | $223.95M |
| Exchange | NGM |
Technical Analysis (OBIO)
Nexqual's technical model rates OBIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 10:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.1 (neutral) |
| vs SMA50 | Below (USD 3.96) |
| MACD | -0.1 (negative) |
Analyst Ratings (OBIO)
Wall Street analysts rate OBIO "Strong Buy" based on 6 analysts, with a mean price target of USD 12.17 (range USD 9–20), per Nexqual as of July 26, 2026 at 10:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 12.17 |
| High Target | USD 20 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (OBIO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $118,170 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 0.26 vs est -0.38 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.43 ▲ beat |
| 2025-06-30 | USD -0.5 vs est -0.51 ▲ beat |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Financials & Fundamentals (OBIO)
| Total Revenue | $32.72M |
|---|---|
| Revenue Growth (YoY) | -87.30% |
| Gross Margin | +99.46% |
| Operating Margin | -20069.09% |
| Profit Margin | -166.96% |
| ROE | -161.12% |
| Debt / Equity | 31.1 |
| Current Ratio | 7.03 |
| Total Cash | $94.40M |
| Total Debt | $15.85M |
| Free Cash Flow | $-25.46M |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Financial Health Score (OBIO)
Nexqual rates Orchestra Biomed Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 10:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $94M cash vs $16M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$25M, burning cash |
| Efficiency | Critical — ROE -161%, ROA -43.0% |
Ownership (OBIO)
| Insider Ownership | +24.57% |
|---|---|
| Institutional Ownership | +42.28% |
| Shares Outstanding | 59.88M |
| Float | 32.76M |
| Short % of Float | +7.04% |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Leadership (OBIO)
Orchestra Biomed Holdings, Inc. is led by David P. Hochman (age 50), Founder, Chairman of the Board of Directors & CEO, per Nexqual as of July 26, 2026 at 10:22 UTC.
| Founder, Chairman of the Board of Directors & CEO | David P. Hochman (age 50) |
|---|---|
| Founder, President, COO & Director | Darren R. Sherman (age 54) |
| Chief Financial Officer | Andrew Lawrence Taylor (age 54) |
| Executive Vice President of Corporate Development & Strategy | William Reed Little (age 54) |
| Vice President of Human Resources | Lisa Daniels |
Major Backers & Investors (OBIO)
Notable institutional backers of Orchestra Biomed Holdings, Inc. include RTW Investments LP, Perceptive Advisors Llc, Alyeska Investment Group, L.p., according to Nexqual as of July 26, 2026 at 10:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 13.87% |
| Perceptive Advisors Llc | 8.41% |
| Alyeska Investment Group, L.p. | 1.67% |
| Propel Bio Management, LLC | 1.5% |
| Millennium Management | 1.17% |
| Affinity Asset Advisors, Llc | 0.67% |
| Fidelity | 0.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.28% |
| BlackRock | 1.57% |
| Geode Capital | 0.81% |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
From Orchestra Biomed Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
- The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
- It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
- In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | USD 1.6 | ▼ 4.76% |
| CBUS | Cibus, Inc. | USD 1.7 | ▼ 5.03% |
| ZURA | Zura Bio Limited | USD 5.23 | ▼ 3.15% |
| OABI | OmniAb, Inc. | USD 2.03 | ▼ 3.79% |
| GNLX | Genelux Corporation | USD 2.89 | ▼ 2.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 10:22 UTC. This page is informational and not investment advice.